Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

MiR-145-5P molecular marker for detecting type 2 diabetes mellitus, and amplification primers and application of miR-145-5P molecular marker

A technology for molecular markers and type 2 diabetes, which is applied in biochemical equipment and methods, microbiological measurement/inspection, DNA/RNA fragments, etc., can solve the problems of non-public detection of type 2 diabetes, and achieve strong pertinence and identification Fast, efficient detection results

Pending Publication Date: 2020-02-14
JINHUA MUNICIPAL CENT HOSPITAL
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, at present, there are no research reports on the use of miRNA molecules as molecular markers for the prediction or diagnosis of type 2 diabetes to detect type 2 diabetes at home and abroad.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • MiR-145-5P molecular marker for detecting type 2 diabetes mellitus, and amplification primers and application of miR-145-5P molecular marker
  • MiR-145-5P molecular marker for detecting type 2 diabetes mellitus, and amplification primers and application of miR-145-5P molecular marker
  • MiR-145-5P molecular marker for detecting type 2 diabetes mellitus, and amplification primers and application of miR-145-5P molecular marker

Examples

Experimental program
Comparison scheme
Effect test

specific Embodiment

[0018] 1. Collection of research objects

[0019] All samples in this study were collected with the approval of the medical research ethics committee of the unit and the informed consent of the patients, including 75 serum samples from the prediabetes group and 112 serum samples from the T2DM group. Collection requirements: T2DM was diagnosed according to the 2015 American Diabetes Association guidelines. Prediabetes was diagnosed according to the criteria of impaired glucose tolerance (IGT). All excluded ①acute and chronic infectious diseases; ②severe heart, brain, liver damage and other endocrine diseases affecting glucose metabolism.

[0020] 2. Use gene chips to screen out circulating miRNAs that have significant differences and may be closely related to the development of T2DM in serum samples of 5 cases of prediabetes (Prediabetes) and 5 cases of T2DM (strictly matched according to age, gender, and BMI). According to the microarray detection technology, the results sho...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a miRNA (micro ribonucleic acid) molecular marker for detecting type 2 diabetes mellitus, and amplification primers and application of the miRNA molecular marker. The molecularmarker has the characteristics that a nucleotide sequence of an miR-145-5P molecular marker is 5'-GUCCAGUUUUCCCAGGAAUCCCU-3'; a nucleotide sequence of a forward amplification primer of the miR-145-5Pmolecular marker is 5'-GAGGGCACACCGTCGCGA-3'; and the molecular marker can be applied to a kit for detecting the type 2 diabetes mellitus. The molecular marker has the advantages that the molecular marker is high in detection efficiency and strong in pertinence and can be used for auxiliary diagnosis, detection or drug screening of the type 2 diabetes mellitus.

Description

technical field [0001] The invention relates to a miRNA molecular marker, in particular to a miRNA molecular marker for detecting type 2 diabetes, an amplification primer and application thereof. Background technique [0002] Diabetes is a serious life-long disease whose prevalence is increasing year by year. There are currently 463 million people with diabetes worldwide, and diabetes accounts for 5%-20% of total health expenditure in most countries. Type 2 diabetes mellitus (T2DM) is a complex metabolic disease characterized by insulin resistance and pancreatic cell failure. T2DM accounts for more than 90% of all diabetes cases. It is estimated that the global population aged 20-79 was 425 million in 2017 and is expected to increase to 629 million by 2045. And with the increase in the incidence of diabetes and the prolongation of life expectancy, type 2 diabetes will be accompanied by various complications such as diabetic retinopathy, cardiovascular disease, renal failur...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/6883C12Q1/6851C12N15/113C12N15/11
CPCC12Q1/6883C12Q1/6851C12Q2600/158C12Q2600/178C12Q2600/166C12Q2531/113C12Q2545/101C12Q2563/107
Inventor 刘艳芬楼雪勇徐晓东聂冬英黄华英王珊珊陈颖婷刘文文王晓倩
Owner JINHUA MUNICIPAL CENT HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com